The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review

IF 4.9 2区医学 Q1 CLINICAL NEUROLOGY

Journal of affective disorders Pub Date : 2025-04-22 DOI:10.1016/j.jad.2025.04.119

Morgan C.H. Cheng , Christine E. Dri , Hana Ballum , Kyle Valentino , William Cheung , Kayla M. Teopiz , Sabrina Wong , Roger S. McIntyre

{"title":"The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review","authors":"Morgan C.H. Cheng , Christine E. Dri , Hana Ballum , Kyle Valentino , William Cheung , Kayla M. Teopiz , Sabrina Wong , Roger S. McIntyre","doi":"10.1016/j.jad.2025.04.119","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The rapid and clinically meaningful antidepressant effects of ketamine and esketamine are well-established in major depressive disorder (MDD) and treatment-resistant depression (TRD) as evidenced by improvement in clinician- and patient-reported depression measures. However, there remains a need to determine how these agents affect patient-reported quality of life (QoL). Herein, we aimed to systematically review extant studies evaluating the effect of ketamine and esketamine on QoL measures.</div></div><div><h3>Methods</h3><div>A literature search was conducted on online databases (PubMed, Scopus, Web of Science, Medline, and clinicaltrials.gov) for articles from inception to September 30th, 2024, reporting on the association between ketamine/esketamine and measures of QoL in persons diagnosed with MDD or TRD. A risk of bias assessment was conducted using the ROBINS-1 tool and the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>Five studies were identified that investigated the association between ketamine/esketamine and measures of QoL in persons with MDD or TRD. Scales used to measure QoL included the WHOQOL-BREF scale, Assessment of Quality of Life 8D test, and the EuroQol-5 Dimension-5 Layers. Statistically significant findings (<em>p</em> < 0.001) suggest that ketamine and esketamine improve measures of QoL in persons with MDD or TRD. However, an overall moderate risk of bias was observed in the papers included in this analysis.</div></div><div><h3>Discussion</h3><div>Extant studies suggest that ketamine and esketamine treatment are associated with improvement in QoL measures in adults with MDD or TRD. Limitations of this study include hetergeneity in the types of QoL scales as well as study study duration among the studies included. Near-term research priorities should endeavour to investigate the effect of ketamine and esketamine on specific domains of QoL, respectively.</div></div>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":"382 ","pages":"Pages 438-442"},"PeriodicalIF":4.9000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165032725006949","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The rapid and clinically meaningful antidepressant effects of ketamine and esketamine are well-established in major depressive disorder (MDD) and treatment-resistant depression (TRD) as evidenced by improvement in clinician- and patient-reported depression measures. However, there remains a need to determine how these agents affect patient-reported quality of life (QoL). Herein, we aimed to systematically review extant studies evaluating the effect of ketamine and esketamine on QoL measures.

Methods

A literature search was conducted on online databases (PubMed, Scopus, Web of Science, Medline, and clinicaltrials.gov) for articles from inception to September 30th, 2024, reporting on the association between ketamine/esketamine and measures of QoL in persons diagnosed with MDD or TRD. A risk of bias assessment was conducted using the ROBINS-1 tool and the Newcastle-Ottawa Scale.

Results

Five studies were identified that investigated the association between ketamine/esketamine and measures of QoL in persons with MDD or TRD. Scales used to measure QoL included the WHOQOL-BREF scale, Assessment of Quality of Life 8D test, and the EuroQol-5 Dimension-5 Layers. Statistically significant findings (p < 0.001) suggest that ketamine and esketamine improve measures of QoL in persons with MDD or TRD. However, an overall moderate risk of bias was observed in the papers included in this analysis.

Discussion

Extant studies suggest that ketamine and esketamine treatment are associated with improvement in QoL measures in adults with MDD or TRD. Limitations of this study include hetergeneity in the types of QoL scales as well as study study duration among the studies included. Near-term research priorities should endeavour to investigate the effect of ketamine and esketamine on specific domains of QoL, respectively.

查看原文本刊更多论文

氯胺酮和艾氯胺酮对重度抑郁症和难治性抑郁症患者生活质量的影响：一项系统综述

氯胺酮和艾氯胺酮对重度抑郁症（MDD）和难治性抑郁症（TRD）的快速和有临床意义的抗抑郁作用已得到证实，临床医生和患者报告的抑郁症措施的改善证明了这一点。然而，仍然需要确定这些药物如何影响患者报告的生活质量（QoL）。在此，我们旨在系统地回顾现有研究评估氯胺酮和艾氯胺酮对生活质量测量的影响。方法在PubMed、Scopus、Web of Science、Medline、clinicaltrials.gov等在线数据库中检索自成立至2024年9月30日的有关氯胺酮/艾氯胺酮与重度抑郁症或重度抑郁症患者生活质量指标相关性的文献。使用ROBINS-1工具和Newcastle-Ottawa量表进行偏倚风险评估。结果有5项研究调查了氯胺酮/艾氯胺酮与重度抑郁症或重度抑郁症患者生活质量之间的关系。用于测量生活质量的量表包括WHOQOL-BREF量表、生活质量评估8D测试和EuroQol-5维度-5层。有统计学意义的发现(p <；0.001)表明氯胺酮和艾氯胺酮可改善重度抑郁症或TRD患者的生活质量。然而，在本分析纳入的论文中观察到总体偏倚风险为中等。现有研究表明氯胺酮和艾氯胺酮治疗与重度抑郁症或重度抑郁症成人患者生活质量的改善有关。本研究的局限性包括所纳入研究的生活质量量表类型的异质性以及研究的持续时间。近期研究重点应分别研究氯胺酮和艾氯胺酮对生活质量特定领域的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of affective disorders 医学-精神病学

CiteScore

10.90

自引率

6.10%

发文量

1319

审稿时长

9.3 weeks

期刊介绍： The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.